Vera Therapeutics stock rose on FDA acceptance of atacicept BLA for priority review in IgAN, a potential multi-billion dollar ...

Preliminary total global full year 2025 revenue of approximately $616 millionPreliminary BRIUMVI U.S. fourth quarter and full year 2025 net ...

Detailed price information for Vera Therapeutics Inc Cl A (VERA-Q) from The Globe and Mail including charting and trades.

Vera Therapeutics, Inc. ('Vera Therapeutics”), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunologic ...

Topline data were announced from the phase 3 INDIGO trial evaluating obexelimab in adults with immunoglobulin G4-related disease.

Atacicept, a novel dual inhibitor of BAFF and APRIL, receives FDA Priority Review for IgA nephropathy treatment in adults.

MNT speaks with three obesity medicine experts to find out more about the FDA-aproved Wegovy pill and how it's different from ...

Explore comprehensive treatments for CIDP, including corticosteroids, plasma exchange, immunoglobulin therapy, and others.

The FDA approved Scinopharm's glatiramer acetate injection, a generic version of Copaxone, to treat multiple sclerosis.

ARCALYST® (rilonacept) 2025 net product revenue of $677.5 million (unaudited), representing ~62% year-over-year growth –– ...

Self-administered injectable contraceptives, which are progestin-only shots taken at home every three months, have been ...

ARCALYST- (rilonacept) 2025 net product revenue of $677.5 million (unaudited), representing ~62% year-over-year growth -- ARCALYST 2026 net product revenue expected to be $900 - $920 million -- KPL-38 ...